Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: A systematic review

The Lancet Infectious Diseases

Volumn 11, Issue 11, 2011, Pages 855-867

  Uyei, Jennifer ^a   Coetzee, David ^b   Macinko, James ^a   Guttmacher, Sally ^a  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ISONIAZID; TUBERCULOSTATIC AGENT;

AFRICA; CD4 LYMPHOCYTE COUNT; CONDOM; COST EFFECTIVENESS ANALYSIS; COUNSELING; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SURVIVAL RATE; TUBERCULOSIS; VIRUS LOAD;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE, INTEGRATED; HIV; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 82455168139     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70145-1     Document Type: Review

References (106)

1. Getahun H, Gunneberg C, Granich R, Nunn P HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010, 50(suppl 3):S201-S207.
2. Progress towards the Millennium Development Goals, 1990-2005 2005, Department of Economic and Social Affairs, UNstats, New York, NY, USA.
3. Global tuberculosis control 2008: surveillance, planning, financing 2008, WHO, World Health Organization, Geneva.
4. Global tuberculosis control 2009: epidemiology, strategy, financing 2009, WHO, World Health Organization, Geneva.
5. Epidemiological fact sheets on HIV and AIDS. Core data on epidemiology and response: Swaziland 2008 update 2008, WHO, UNAIDSUNAIDS, UNICEFUNICEF, UNAIDS, World Health Organization, UNICEF, Geneva.
6. Gandhi NR, Moll AP, Lalloo U, et al. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 2009, 50:37-43. for the Tugella Ferry Care and Research (TFCaRes) Collaboration.
7. de Jong BC, Israelski DM, Corbett EL, Small PM Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med 2004, 55:283-301.
8. Kwara A, Flanigan TP, Carter EJ Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 2005, 9:248-257.
9. Anderson SR, Maher D An analysis of interaction between TB and HIV/AIDS programmes in sub-Saharan Africa 2001, World Health Organization, Geneva.
10. Friedland G, Harries A, Coetzee D Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies. J Infect Dis 2007, 196(suppl 1):S114-S123.
11. Tsiouris SJ, Gandhi NR, El-Sadr WM, Gerald F Tuberculosis and HIV-needed: a new paradigm for the control and management of linked epidemics. J Int AIDS Soc 2007, 9:62.
12. Coetzee D, Hilderbrand K, Goemaere E, Matthys F, Boelaert M Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health 2004, 9:A11-A15.
13. Harries AD, Hargreaves NJ, Chimzizi R, Salaniponi FM Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential. Bull World Health Organ 2002, 80:464-469.
14. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001, 358:410-414.
15. Maher D Re-thinking global health sector efforts for HIV and tuberculosis epidemic control: promoting integration of programme activities within a strengthened health system. BMC Public Health 2010, 10:394.
16. Levine R, Oomman N Global HIV/AIDS funding and health systems: searching for the win-win. J Acquir Immune Defic Syndr 2009, 52(suppl 1):S3-S5.
17. Topp SM, Chipukuma JM, Giganti M, et al. Strengthening health systems at facility-level: feasibility of integrating antiretroviral therapy into primary health care services in lusaka, zambia. PLoS One 2010, 5:e11522.
18. Maher D Implications of the global financial crisis for the response to diseases of poverty within overall health sector development: the case of tuberculosis. Trop Med Int Health 2010, 15:11-17.
19. Bosman MC Health sector reform and tuberculosis control: the case of Zambia. Int J Tuberc Lung Dis 2000, 4:606-614.
20. Horton R African AIDS beyond Mbeki: tripping into anarchy. Lancet 2000, 356:1541-1542.
21. Report of a "lessons learnt" workshop on the six ProTEST pilot projects in Malawi, South Africa, and Zambia 2004, WHO, WHO, Geneva.
22. Interim policy on collaborative TB/HIV activities 2004, WHO, World Health Organization, Geneva.
23. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009, 62:e1-34.
24. Moher D, Liberati A, Tetzlaff J, Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62:1006-1012. for the PRISMA Group.
25. Shadish WR, Cook TD, Campbell DT Experimental and quasi-experimental designs for generalized causal inference 2002, Houghton Mifflin, Boston.
26. A guide to monitoring and evaluation for collaborative TB/HIV activities 2009, WHO, World Health Organization, Geneva.
27. Bowling A, Ebrahim S Handbood of health research methods: investigation, measurement, and analysis 2005, Open Univsersity Press, McGraw Hill, Berkshire.
28. Toolkit for monitoring health systems strengthening 2008, WHO, World Health Organization, Geneva.
29. Shah S, Demissie M, Lambert L, et al. Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr 2009, 50:537-545.
30. Wesen A, Mitike G Screening and case detection for tuberculosis among people living with HIV in Addis Ababa, Ethiopia. Ethiop Med J 2009, 47:109-115.
31. Gasana M, Vandebriel G, Kabanda G, et al. Integrating tuberculosis and HIV care in rural Rwanda. Int J Tuberc Lung Dis 2008, 12(suppl 1):39-43.
32. Lawn SD, Myer L, Bekker LG, Wood R Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006, 20:1605-1612.
33. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009, 23:1875-1880.
34. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010, 24:1323-1328.
35. Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis 2004, 8:792-795.
36. Saranchuk P, Boulle A, Hilderbrand K, et al. Evaluation of a diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV-infected adults. S Afr Med J 2007, 97:517-523.
37. Ngowi BJ, Mfinanga SG, Bruun JN, Morkve O Pulmonary tuberculosis among people living with HIV/AIDS attending care and treatment in rural northern Tanzania. BMC Public Health 2008, 8:341.
38. Baalwa J, Mayanja-Kizza H, Kamya MR, John L, Kambugu A, Colebunders R Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci 2008, 8:190-195.
39. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007, 21:713-719.
40. Mugisha B, Bock N, Mermin J, et al. Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda. Int J Tuberc Lung Dis 2006, 10:761-767.
41. Were W, Moore D, Ekwaru P, et al. A simple screening tool for active tuberculosis in HIV-infected adults receiving antiretroviral treatment in Uganda. Int J Tuberc Lung Dis 2009, 13:47-53.
42. Lawn SD, Badri M, Wood R Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005, 19:2109-2116.
43. Mosimaneotsile B, Mathoma A, Chengeta B, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. J Acquir Immune Defic Syndr 2009, 54:71-77.
44. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009, 23:631-636.
45. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings?. Int J Tuberc Lung Dis 2005, 9:263-269.
46. Aisu T, Raviglione MC, van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 1995, 9:267-273.
47. Lugada ES, Watera C, Nakiyingi J, et al. Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda. Int J Tuberc Lung Dis 2002, 6:326-331.
48. Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis 2007, 11:1114-1120.
49. Dembélé M, Saleri N, Carvalho AC, et al. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis 2010, 14:318-323.
50. Njozing NB, Miguel SS, Tih PM, Hurtig AK Assessing the accessibility of HIV care packages among tuberculosis patients in the Northwest Region, Cameroon. BMC Public Health 2010, 10:129.
51. Abouya L, Coulibaly IM, Wiktor SZ, et al. The Côte d'Ivoire national HIV counseling and testing program for tuberculosis patients: implementation and analysis of epidemiologic data. AIDS 1998, 12:505-512.
52. Van Rie A, Sabue M, Jarrett N, et al. Counseling and testing TB patients for HIV: evaluation of three implementation models in Kinshasa, Congo. Int J Tuberc Lung Dis 2008, 12(3 suppl 1):73-78.
53. Corneli A, Jarrett NM, Sabue M, et al. Patient and provider perspectives on implementation models of HIV counseling and testing for patients with TB. Int J Tuberc Lung Dis 2008, 12(3 suppl 1):79-84.
54. Appiah LT, Havers F, Gibson J, Kay M, Sarfo F, Chadwick D Efficacy and acceptability of rapid, point-of-care HIV testing in two clinical settings in Ghana. AIDS Patient Care STDS 2009, 23:365-369.
55. Huerga H, Spillane H, Guerrero W, Odongo A, Varaine F Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya. Int J Tuberc Lung Dis 2010, 14:611-615.
56. Kwange SO, Budambula NL Effectiveness of anti-tuberculosis treatment among patients receiving highly active antiretroviral therapy at Vihiga district hospital in 2007. Indian J Med Microbiol 2010, 28:15-21.
57. Odhiambo J, Kizito W, Njoroge A, et al. Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya. Int J Tuberc Lung Dis 2008, 12(3 suppl 1):38-63.
58. Boeree MJ, Sauvageot D, Banda HT, Harries AD, Zijlstra EE Efficacy and safety of two dosages of cotrimoxazole as preventive treatment for HIV-infected Malawian adults with new smear-positive tuberculosis. Trop Med Int Health 2005, 10:723-733.
59. Chimzizi RB, Harries AD, Manda E, Khonyongwa A, Salaniponi FM Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. Int J Tuberc Lung Dis 2004, 8:938-944.
60. Chimzizi R, Gausi F, Bwanali A, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole are associated with improved TB treatment outcomes under routine conditions in Thyolo District, Malawi. Int J Tuberc Lung Dis 2004, 8:579-585.
61. Mwaungulu FB, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004, 82:354-363.
62. Zachariah R, Harries AD, Manzi M, et al. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS One 2006, 1:e121.
63. Zachariah R, Spielmann MP, Harries AD, Gomani P, Bakali E Co-trimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo, Malawi. Int J Tuberc Lung Dis 2002, 6:1046-1050.
64. Zachariah R, Spielmann MP, Harries AD, Salaniponi FL Voluntary counselling, HIV testing and sexual behaviour among patients with tuberculosis in a rural district of Malawi. Int J Tuberc Lung Dis 2003, 7:65-71.
65. Zachariah R, Spielmann MP, Chinji C, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003, 17:1053-1061.
66. Jack C, Lalloo U, Karim QA, et al. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004, 36:929-934.
67. Kigozi NG, Heunis JC, Chikobvu P, van den Berg H, van Rensburg HC, Wouters E Predictors of uptake of human immunodeficiency virus testing by tuberculosis patients in Free State Province, South Africa. Int J Tuberc Lung Dis 2010, 14:399-405.
68. Pope DS, Deluca AN, Kali P, et al. A cluster-randomized trial of provider-initiated (opt-out) HIV counseling and testing of tuberculosis patients in South Africa. J Acquir Immune Defic Syndr 2008, 48:190-195.
69. Pope DS, Atkins S, DeLuca AN, et al. South African TB nurses' experiences of provider-initiated HIV counseling and testing in the Eastern Cape Province: a qualitative study. AIDS Care 2010, 22:238-245.
70. Sendagire I, Schreuder I, Mubiru M, Schim van der Loeff M, Cobelens F, Konde-Lule J Low HIV testing rates among tuberculosis patients in Kampala, Uganda. BMC Public Health 2010, 10:177.
71. Srikantiah P, Lin R, Walusimbi M, et al. Elevated HIV seroprevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention. Int J Tuberc Lung Dis 2007, 11:168-174.
72. Harris JB, Hatwiinda SM, Randels KM, et al. Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia. Int J Tuberc Lung Dis 2008, 12:773-779.
73. Wiktor SZ, Abouya L, Angoran H, et al. Effect of an HIV counseling and testing program on AIDS-related knowledge and practices in tuberculosis clinics in Abidjan, Côte d'Ivoire. Int J Tuberc Lung Dis 2004, 8:445-450.
74. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999, 353:1469-1475.
75. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008, 337:a257. for the UNZA-UCLMS Project LUCOT Collaboration.
76. Bell JC, Rose DN, Sacks HS Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS 1999, 13:1549-1556.
77. Chi BH, Fusco H, Sinkala M, Goldenberg RL, Stringer JS Cost and enrollment implications of targeting different source population for an HIV treatment program. J Acquir Immune Defic Syndr 2005, 40:350-355.
78. Foster S, Godfrey-Faussett P, Porter J Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997, 11:919-925.
79. Hausler HP, Sinanovic E, Kumaranayake L, et al. Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 2006, 84:528-536.
80. Shrestha RK, Mugisha B, Bunnell R, et al. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda. Int J Tuberc Lung Dis 2006, 10:656-662.
81. Shrestha RK, Mugisha B, Bunnell R, et al. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int J Tuberc Lung Dis 2007, 11:747-754.
82. Kumaranayake L The real and the nominal? Making inflationary adjustments to cost and other economic data. Health Policy Plan 2000, 15:230-234.
83. Sinanovic E, Floyd K, Dudley L, Azevedo V, Grant R, Maher D Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa. Int J Tuberc Lung Dis 2003, 7(9 suppl 1):S56-S62.
84. Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:93-102.
85. Nunn P, Mungai M, Nyamwaya J, et al. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tuber Lung Dis 1994, 75:25-32.
86. Elliott AM, Namaambo K, Allen BW, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis 1993, 74:191-194.
87. van der Sande MA, Schim van der Loeff MF, Bennett RC, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004, 18:1933-1941.
88. Badri M, Wilson D, Wood R Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059-2064.
89. Akolo C, Adetifa I, Shepperd S, Volmink J Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, 1:CD000171.
90. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic-when will we act?. Lancet 2010, 375:1906-1919.
91. Joshi R, Reingold AL, Menzies D, Pai M Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med 2006, 3:e494.
92. WHO policy on TB infection control in health-care facilities, congregate settings, and households 2009, WHO, World Health Organization, Geneva.
93. Bock NN, Jensen PA, Miller B, Nardell E Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007, 196(suppl 1):S108-S113.
94. Shenoi SV, Escombe AR, Friedland G Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis 2010, 50(suppl 3):S231-S237.
95. Global tuberculosis control: a short update to the 2009 report 2009, WHO, World Health Organization, Geneva.
96. Nateniyom S, Jittimanee SX, Viriyakitjar D, Jittimanee S, Keophaithool S, Varma JK Provider-initiated diagnostic HIV counselling and testing in tuberculosis clinics in Thailand. Int J Tuberc Lung Dis 2008, 12:955-961.
97. Thomas BE, Dewan PK, Vijay S, et al. Perceptions of tuberculosis patients on provider-initiated HIV testing and counseling-a study from south India. PLoS One 2009, 4:e8389.
98. Bassett IV, Walensky RP Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis 2010, 50(suppl 3):S77-S84.
99. Bassett IV, Regan S, Chetty S, et al. Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS 2010, 24(suppl 1):S37-S44.
100. Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006, 193:1437-1440.
101. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010, 10:155-166.
102. Guidance for PEPFAR Partnership Frameworks and Partnership Framework Implementation Plans. Washington, DC, USA The United States President's Emergency Plan for AIDS Relief. http://USA.gov.
103. The World Bank's commitment to HIV/ADS in Africa: our agenda for action, 2007-2011 2008, The International Bank for Reconstruction and Development, The World BankThe World Bank, The World Bank, Washington, DC.
104. The Global Fund to Fight AIDS, tuberculosis and Malaria. Fact sheet: The Global Fund's approach to health systems strengthening. Geneva; 2008.
105. Okot-Chono R, Mugisha F, Adatu F, Madraa E, Dlodlo R, Fujiwara P Health system barriers affecting the implementation of collaborative TB-HIV services in Uganda. Int J Tuberc Lung Dis 2009, 13:955-961.
106. Evashwick CJ The continuum of long-term care 2005, Thomson Delmar Learning, Inc, Clifton Park. 3rd edn.